FDA Finalizes REMS Guidance
The FDA guidance defines changes to approved risk evaluation and mitigation strategies and clarifies submission guidelines.
FDA published the final version of its REMS guidance document, Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry, on July 9, 2019. The guidance provides information on types of approved risk evaluation and mitigation strategies (REMS) and how applicants should submit changes to an approved REMS. The guidance also clarifies the differences between modifications of a REMS and revisions of a REMS.
FDA timeframes for assessing REMS changes-including revisions, minor modifications, major modifications, modifications due to safety labeling changes, and multiple types of REMS changes-are also included in the document. An appendix provides detailed submission procedures.
The guidance applies to all types of REMS but does not address additional submission procedures that may apply to application holders proposing changes to a shared system and that use a drug master file for their REMS submission.
Source: FDA
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
